Compare AUUD & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUUD | NXTS |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | Israel |
| Employees | 5 | 9 |
| Industry | Computer Software: Prepackaged Software | Agricultural Chemicals |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 3.6M |
| IPO Year | N/A | N/A |
| Metric | AUUD | NXTS |
|---|---|---|
| Price | $1.69 | $5.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.1M | 40.9K |
| Earning Date | 05-11-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.55 |
| 52 Week High | $10.10 | $6.75 |
| Indicator | AUUD | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 49.08 | 54.12 |
| Support Level | $0.74 | $3.97 |
| Resistance Level | $1.95 | $5.31 |
| Average True Range (ATR) | 0.28 | 0.71 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 33.60 | 38.28 |
Auddia Inc is a United States-based company. It operates through its proprietary AI platform for audio and is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. The group Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Its flagship audio superapp, called faidr, delivers multiple industry firsts, including: Ad-free listening on any AM/FM radio station, Content skipping across any AM/FM station, One-touch skipping of entire podcast ad breaks, and Integrated artist discovery experiences.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.